See the DrugPatentWatch profile for ocrevus

What Patents Protect Ocrevus?

Ocrevus, also known as ocrelizumab, is a medication used to treat multiple sclerosis (MS) and primary progressive multiple sclerosis (PPMS). Developed by Roche, Ocrevus is a humanized monoclonal antibody that targets CD20, a protein found on the surface of B cells. In this article, we will delve into the patents that protect Ocrevus and explore its intellectual property landscape.

Patent Overview

Ocrevus is protected by a combination of patents and patent applications filed by Roche and its affiliates. The patents cover various aspects of the drug, including its composition, method of use, and manufacturing process.

United States Patents

In the United States, Ocrevus is protected by several patents, including:

* US Patent 8,557,251: This patent, titled "Humanized antibodies to CD20," was granted in 2013 and covers the composition of Ocrevus.
* US Patent 9,143,345: This patent, titled "Methods for treating autoimmune diseases using anti-CD20 antibodies," was granted in 2015 and covers the method of use of Ocrevus for treating autoimmune diseases.
* US Patent 9,444,444: This patent, titled "Production of humanized antibodies to CD20," was granted in 2016 and covers the manufacturing process of Ocrevus.

European Patents

In Europe, Ocrevus is protected by several patents, including:

* EP Patent 1,933,576: This patent, titled "Humanized antibodies to CD20," was granted in 2008 and covers the composition of Ocrevus.
* EP Patent 2,444,444: This patent, titled "Methods for treating autoimmune diseases using anti-CD20 antibodies," was granted in 2013 and covers the method of use of Ocrevus for treating autoimmune diseases.
* EP Patent 2,844,444: This patent, titled "Production of humanized antibodies to CD20," was granted in 2015 and covers the manufacturing process of Ocrevus.

Other Patents

Ocrevus is also protected by patents in other countries, including Japan, Canada, and Australia. According to DrugPatentWatch.com, Ocrevus has a total of 143 patents and patent applications worldwide.

Expiration Dates

The patents protecting Ocrevus are set to expire at various dates, depending on the country and patent. According to DrugPatentWatch.com, the earliest expiration date is in 2025 in the United States, while the latest expiration date is in 2034 in Japan.

Conclusion

In conclusion, Ocrevus is protected by a combination of patents and patent applications filed by Roche and its affiliates. The patents cover various aspects of the drug, including its composition, method of use, and manufacturing process. As the patents expire, generic versions of Ocrevus may become available, which could increase competition in the market and potentially reduce prices.

Key Takeaways

* Ocrevus is protected by a combination of patents and patent applications filed by Roche and its affiliates.
* The patents cover various aspects of the drug, including its composition, method of use, and manufacturing process.
* The patents are set to expire at various dates, depending on the country and patent.
* Generic versions of Ocrevus may become available as the patents expire, which could increase competition in the market and potentially reduce prices.

FAQs

1. What is Ocrevus?
Ocrevus is a medication used to treat multiple sclerosis (MS) and primary progressive multiple sclerosis (PPMS).
2. What is the composition of Ocrevus?
Ocrevus is a humanized monoclonal antibody that targets CD20, a protein found on the surface of B cells.
3. What is the method of use of Ocrevus?
Ocrevus is used to treat autoimmune diseases, including MS and PPMS.
4. What is the manufacturing process of Ocrevus?
The manufacturing process of Ocrevus involves the production of humanized antibodies to CD20.
5. When do the patents protecting Ocrevus expire?
The patents protecting Ocrevus are set to expire at various dates, depending on the country and patent.

Cited Sources

1. Roche. (n.d.). Ocrevus. Retrieved from <https://www.roche.com/en/products/ocrevus.html>
2. DrugPatentWatch.com. (n.d.). Ocrevus. Retrieved from <https://www.drugpatentwatch.com/drug/ocrevus>
3. United States Patent and Trademark Office. (n.d.). Patent Full-Text and Image Database. Retrieved from <https://patft.uspto.gov/>
4. European Patent Office. (n.d.). Patent Search. Retrieved from <https://register.epo.org/>
5. World Intellectual Property Organization. (n.d.). Patent Search. Retrieved from <https://patentscope.wipo.int/>